SAN
DIEGO, Sept. 20, 2024 /PRNewswire/ -- Kintara
Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical
company focused on the development of new solid tumor cancer
therapies, today announced it adjourned the Special Meeting of
Stockholders (the "Special Meeting") held on September 20, 2024. The Special Meeting will
reconvene on October 4, 2024 at
9:00 a.m., Eastern Time at
www.viewproxy.com/kintarasm/2024.
The Company has determined to adjourn the Special Meeting
because the voting threshold has not been reached on Proposals 3
& 5, both submitted to stockholders of record to, respectively,
(i) approve an amendment to the Kintara Charter (as defined below)
to increase the number of authorized shares of Kintara to
400,000,000, to be effected at such time and date as determined by
the Kintara board of directors in its sole discretion ("Proposal
3") and (ii) approve the reincorporation of Kintara from the
State of Nevada to the
State of Delaware and the plan of
conversion attached to Kintara's definitive proxy statement and
final prospectus filed with the Securities and Exchange Commission
(the "SEC") on August 19, 2024 as
Annex D, including the certificate of incorporation of Kintara
post-reincorporation in Delaware
(the "Kintara Charter") attached thereto as Annex G ("Proposal 5"),
both in connection with Kintara's proposed Merger with TuHURA
Biosciences, Inc. ("TuHURA").
The close of business on August 14,
2024 (the "Record Date") will continue to be the record date
for the determination of stockholders of the Company entitled to
attend and vote at the Special Meeting. Stockholders who have
already voted do not need to recast their votes. Proxies previously
submitted in respect of the Special Meeting will be voted at the
adjourned Special Meeting unless properly revoked in accordance
with the procedures described in the Company's definitive proxy
statement and final prospectus.
About TuHURA Biosciences, Inc.
TuHURA Biosciences,
Inc. is a Phase 3 registration-stage immuno-oncology company
developing novel technologies to overcome resistance to cancer
immunotherapy. TuHURA's lead product candidate, IFx-2.0, is
designed to overcome primary resistance to checkpoint inhibitors.
TuHURA is preparing to initiate a planned single randomized
placebo-controlled Phase 3 registration trial of IFx-2.0
administered as an adjunctive therapy to Keytruda®
(pembrolizumab) in first line treatment for advanced or metastatic
Merkel Cell Carcinoma.
In addition, TuHURA is leveraging its Delta receptor technology
to develop novel bi-functional antibody drug conjugates (ADCs),
targeting Myeloid Derived Suppressor Cells to inhibit their immune
suppressing effects on the tumor microenvironment to prevent T cell
exhaustion and acquired resistance to checkpoint inhibitors and
cellular therapies.
For more information, please visit tuhurabio.com and
connect with TuHURA on Facebook, X,
and LinkedIn.
ABOUT KINTARA THERAPEUTICS, INC.
Located in
San Diego, California, Kintara is
dedicated to the development of novel cancer therapies for patients
with unmet medical needs. Kintara is developing therapeutics for
clear unmet medical needs with reduced risk development programs.
Kintara's lead program is REM-001 Therapy for cutaneous metastatic
breast cancer (CMBC).
Kintara has a proprietary, late-stage photodynamic therapy
platform that holds promise as a localized cutaneous, or visceral,
tumor treatment as well as in other potential indications. REM-001
Therapy, which consists of the laser light source, the light
delivery device, and the REM-001 drug product, has been previously
studied in four Phase 2/3 clinical trials in patients with CMBC who
had previously received chemotherapy and/or failed radiation
therapy. In CMBC, REM-001 has a clinical efficacy to date of 80%
complete responses of CMBC evaluable lesions and an existing robust
safety database of approximately 1,100 patients across multiple
indications.
Kintara Therapeutics, Inc. is headquartered in San Diego, California. For more information,
visit www.kintara.com or follow us on X
at @Kintara_Thera, Facebook and LinkedIn.
No Offer or Solicitation
This communication
shall not constitute an offer to sell or the solicitation of an
offer to buy any securities or a solicitation of any proxy,
consent, authorization, vote or approval, nor shall there be any
sale of securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such
jurisdiction.
No offering of securities shall be made except by means of a
prospectus meeting the requirements of Section 10 of the U.S.
Securities Act of 1933, as amended (the "Securities Act").
Additional Information About the Proposed Merger and Where to
Find It
This communication does not constitute an offer to
buy or sell or the solicitation of an offer to buy or sell any
securities or a solicitation of any vote or approval. This
communication relates to the proposed Merger of Kintara and TuHURA.
In connection with the proposed Merger, Kintara has filed relevant
materials with the SEC, including a Registration Statement on Form
S-4 that contains a definitive proxy statement and final prospectus
of Kintara (the "proxy statement/prospectus"). This Registration
Statement was declared effective on August
13, 2024 and Kintara has filed or may file other documents
regarding the proposed Merger with the SEC. This press release is
not a substitute for the Registration Statement or for any other
document that Kintara has filed or may file with the SEC in
connection with the proposed Merger. No offering of securities
shall be made, except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act. INVESTORS AND
SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, THE
DEFINITIVE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT
DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR
SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY,
WHEN THEY BECOME AVAILABLE, BECAUSE THEY CONTAIN AND THEY WILL
CONTAIN IMPORTANT INFORMATION ABOUT KINTARA, TUHURA, THE PROPOSED
MERGER AND RELATED MATTERS THAT STOCKHOLDERS SHOULD CONSIDER BEFORE
MAKING ANY DECISION REGARDING THE PROPOSED MERGER. A definitive
proxy statement/prospectus has been sent to Kintara's stockholders.
Investors and security holders will be able to obtain the proxy
statement/prospectus and other documents filed by Kintara with the
SEC (when available) free of charge from the SEC's website at
www.sec.gov. In addition, investors and stockholders should note
that Kintara communicates with investors and the public using its
website (www.kintara.com), the investor relations website
(https://www.kintara.com/investors) where anyone will be able to
obtain free copies of the definitive proxy statement/prospectus and
other documents filed by Kintara with the SEC, and stockholders are
urged to read the definitive proxy statement/prospectus and the
other relevant materials (when they become available) before making
any voting or investment decision with respect to the proposed
Merger.
Participants in the Solicitation
Kintara, TuHURA and
their respective directors and executive officers and other members
of management and employees and certain of their respective
significant stockholders may be deemed to be participants in the
solicitation of proxies from Kintara stockholders in respect of the
proposed Merger. Information about Kintara's directors and
executive officers is available in Kintara's proxy statement, which
was filed with the SEC on May 17,
2024 for the 2024 Annual Meeting of Stockholders, Kintara's
Annual Report on Form 10-K for the fiscal year ended June 30, 2023, which was filed with the SEC on
September 18, 2023 and the definitive
proxy statement/prospectus. Information regarding the persons who
may, under the rules of the SEC, be deemed participants in the
proxy solicitation and a description of their direct and indirect
interests, by security holding or otherwise, has been and will be
contained in the definitive proxy statement/prospectus and other
relevant materials to be filed with the SEC regarding the proposed
Merger when they become available. Investors should read the
definitive proxy statement/prospectus carefully when it becomes
available before making any voting or investment decisions. You may
obtain free copies of these documents from the SEC and Kintara as
indicated above.
FORWARD-LOOKING STATEMENTS
This press release contains
forward-looking statements based upon Kintara's and TuHURA's
current expectations. This communication contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are identified by
terminology such as "believe," "may," "will," "estimate,"
"continue," "anticipate," "intend," "could," "should," "would,"
"project," "plan," "expect," "goal," "seek," "future," "likely" or
the negative or plural of these words or similar expressions.
Examples of such forward-looking statements include but are not
limited to express or implied statements regarding Kintara's or
TuHURA's management team's expectations, hopes, beliefs, intentions
or strategies regarding the future including, without limitation,
statements regarding: the proposed Merger and the expected effects,
perceived benefits or opportunities and related timing with respect
thereto, expectations regarding clinical trials and research and
development programs, in particular with respect to TuHURA's
IFx-Hu2.0 product candidate novel bifunctional ADCs, and any
developments or results in connection therewith; the anticipated
timing of the results from those studies and trials; expectations
regarding the use of capital resources, including the net proceeds
from the financing that closed in connection with the signing of
the definitive agreement, and the time period over which the
combined company's capital resources will be sufficient to fund its
anticipated operations; and the expected trading of the combined
company's stock on the Nasdaq Capital Market. These statements are
only predictions. Kintara and TuHURA have based these
forward-looking statements largely on their then-current
expectations and projections about future events, as well as the
beliefs and assumptions of management. Forward-looking statements
are subject to a number of risks and uncertainties, many of which
involve factors or circumstances that are beyond each of Kintara's
and TuHURA's control, and actual results could differ materially
from those stated or implied in forward-looking statements due to a
number of factors, including but not limited to: (i) the risk that
the conditions to the closing or consummation of the proposed
Merger are not satisfied, including the failure to obtain Kintara
stockholder approval for the proposed Merger; (ii) uncertainties as
to the timing of the consummation of the proposed Merger and the
ability of each of Kintara and TuHURA to consummate the
transactions contemplated by the proposed Merger; (iii) risks
related to Kintara's and TuHURA's ability to correctly estimate
their respective operating expenses and expenses associated with
the proposed Merger, as applicable, as well as uncertainties
regarding the impact any delay in the closing would have on the
anticipated cash resources of the resulting combined company upon
closing and other events and unanticipated spending and costs that
could reduce the combined company's cash resources; (iv) the
occurrence of any event, change or other circumstance or condition
that could give rise to the termination of the proposed Merger by
either Kintara or TuHURA; (v) the effect of the announcement or
pendency of the proposed Merger on Kintara's or TuHURA's business
relationships, operating results and business generally; (vi) costs
related to the proposed Merger; (vii) the outcome of any legal
proceedings that may be instituted against Kintara, TuHURA, or any
of their respective directors or officers related to the Merger
Agreement or the transactions contemplated thereby; (vii) the
ability of Kintara or TuHURA to protect their respective
intellectual property rights; (viii) competitive responses to the
proposed Merger; (ix) unexpected costs, charges or expenses
resulting from the proposed Merger; (x) whether the combined
business of TuHURA and Kintara will be successful; (xi)
legislative, regulatory, political and economic developments; and
(xii) additional risks described in the "Risk Factors" section of
Kintara's Annual Report on Form 10-K for the fiscal year ended
June 30, 2023, and the Registration
Statement on Form S-4 related to the proposed Merger filed with the
SEC. Additional assumptions, risks and uncertainties are described
in detail in Kintara's registration statements, reports and other
filings with the SEC, which are available on Kintara's website, and
at www.sec.gov. Accordingly, you should not rely upon
forward-looking statements as predictions of future events. Neither
Kintara nor TuHURA can assure you that the events and circumstances
reflected in the forward-looking statements will be achieved or
occur, and actual results could differ materially from those
projected in the forward-looking statements. The forward-looking
statements made in this communication relate only to events as of
the date on which the statements are made. Except as required by
applicable law or regulation, Kintara and TuHURA undertake no
obligation to update any forward-looking statement to reflect
events or circumstances after the date on which the statement is
made or to reflect the occurrence of unanticipated events.
Investors should not assume that any lack of update to a previously
issued "forward-looking statement" constitutes a reaffirmation of
that statement.
INVESTOR INQUIRIES:
Robert E. Hoffman
Kintara Therapeutics
rhoffman@kintara.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kintara-therapeutics-announces-adjournment-of-special-meeting-of-stockholders-until-october-4-2024-302253764.html
SOURCE Kintara Therapeutics